Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort by Utriainen, Pauliina et al.
March 2018 | Volume 9 | Article 961
Original research
published: 15 March 2018
doi: 10.3389/fendo.2018.00096
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Giuliana Valerio, 
Università degli Studi di Napoli 
Parthenope, Italy
Reviewed by: 
Gianpaolo De Filippo, 
Bicêtre Hospital, France  
Luisa De Sanctis, 
Università degli Studi di Torino, Italy
*Correspondence:
Pauliina Utriainen 
pauliina.utriainen@hus.fi
Specialty section: 
This article was submitted to 
Pediatric Endocrinology, 
a section of the journal 
Frontiers in Endocrinology
Received: 11 December 2017
Accepted: 27 February 2018
Published: 15 March 2018
Citation: 
Utriainen P, Valta H, Björnsdottir S, 
Mäkitie O and Horemuzova E (2018) 
Polyostotic Fibrous Dysplasia 
With and Without McCune–Albright 
Syndrome—Clinical Features 
in a Nordic Pediatric Cohort. 
Front. Endocrinol. 9:96. 
doi: 10.3389/fendo.2018.00096
Polyostotic Fibrous Dysplasia  
With and Without Mccune–albright 
syndrome—clinical Features  
in a nordic Pediatric cohort
Pauliina Utriainen1,2,3,4*, Helena Valta1,2, Sigridur Björnsdottir5, Outi Mäkitie1,2,3,5,6  
and Eva Horemuzova4,7
1 Children’s Hospital, Helsinki University Central Hospital, Helsinki, Finland, 2 Children’s Hospital, University of Helsinki, 
Helsinki, Finland, 3 Folkhälsan Research Center, Helsinki, Finland, 4 Department of Women’s and Children’s Health, Karolinska 
Institute, Stockholm, Sweden, 5 Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden, 
6 Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, 7 Pediatric Endocrinology Unit, Astrid 
Lindgren’s Children Hospital, Karolinska University Hospital, Stockholm, Sweden
Objective: Fibrous dysplasia (FD) presents as skeletal lesions in which normal bone is 
replaced by abnormal fibrous tissue due to mosaic GNAS mutation. McCune–Albright 
syndrome (MAS) refers to FD combined with skin (café-au-lait) and endocrine manifes-
tations. This study describes the clinical childhood manifestations of polyostotic FD and 
MAS in a Nordic cohort.
Patients and design: We retrospectively reviewed a cohort of pediatric patients (n = 16) 
with polyostotic FD with or without MAS diagnosed and followed in two Nordic Pediatric 
tertiary clinics between 1996 and 2017.
results: Half of the 16 patients with polyostotic FD presented with MAS. All patients 
with MAS (n =  8) had café-au-lait spots, and either gonadotropin-independent pre-
cocious puberty (PP) (girls; n = 5) or abnormal testicle structure (boys, n = 3). None 
manifested hyperthyroidism or growth hormone excess. Mild hypophosphatemia was 
common (11/16), but none had signs of hypophosphatemic rickets. Craniofacial bone 
involvement was found in 12 patients (75%); in 5 of these, skeletal lesions were limited 
to craniofacial area. One child with craniofacial disease had lost vision due to optic nerve 
damage. Eleven (69%) patients had sustained a fracture at FD lesion, over half of them 
requiring surgical fixation of the fracture, most commonly in the proximal femur. The first 
symptoms leading to FD/MAS diagnosis included skull/facial asymmetry (n =  4), PP 
(n = 3), abnormal gait (n = 3), pathologic fracture (n = 3), wide-spread café-au-lait spots 
(n = 1), headache (n = 1), and vision loss (n = 1).
conclusion: Polyostotic FD and MAS remain diagnostic and therapeutic challenges 
because of the broad clinical spectrum. Recurrent fractures, pain, and even vision loss 
may impair the quality of life in children with FD.
Keywords: fibrous dysplasia, polyostotic, Mccune–albright syndrome, mosaicism, bone fractures, craniofacial 
abnormalities, precocious puberty, café-au-lait spots
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inTrODUcTiOn
Fibrous dysplasia (FD) is a genetic, non-inheritable skeletal 
disorder in which normal bone is replaced by abnormal bone 
structure in the dysplastic FD lesions (1). FD is caused by somatic 
activating mutation in the GNAS gene, coding for the α-subunit 
of the stimulatory G protein (Gs) (2, 3). These assumingly post-
zygotic missense mutations cause genetic mosaicism and lead to 
constitutional activation of cAMP regulating Gsα in the affected 
cells (1, 3). Gsα is widely expressed, and therefore the disease 
manifestations are strikingly heterogenous.
The clinical spectrum of these conditions is broad, depending 
on the distribution of genetic mosaicism. Skeletal lesions with 
abnormal bone structure may present only in one bone (monos-
totic FD; in 70–85% of patients) or in multiple sites (polyostotic 
FD; 15–30%) and can lead to deformities, fractures, functional 
impairment, and pain (1). In patients with craniofacial FD, facial 
asymmetry is common, and compression of the optic nerve can 
cause impairment of vision. Skeletal lesions usually develop during 
the first decade of life (4). FD can occur alone or in combination 
with typical café-au-lait skin spots and/or endocrinopathies due 
to overproduction of hormones as a part of McCune–Albright 
syndrome (MAS) (5, 6). While café-au-lait spots are typically 
the earliest extra-skeletal manifestation in MAS, the most com-
mon endocrine manifestations include precocious puberty (PP), 
hyperthyroidism, and renal phosphate wasting with or without 
rickets/osteomalacia (7, 8). Acromegaly caused by growth hor-
mone (GH) excess is also rather common manifestation in MAS 
(9). According to the clinical definition by Collins and coworkers, 
the phenotype of MAS can include any combination of skel-
etal, skin, and endocrine features (1). However, the original and 
stricter definition of MAS, which is still sometimes used (10, 11), 
requires the presence of all three manifestations—skeletal, skin, 
and endocrine—for diagnosis.
Polyostotic FD, and particularly MAS is a rare condition. The 
prevalence of MAS ranges between 1/100,000 and 1/1,000,000 
with no ethnic differences in the disease frequency (6). The exact 
prevalence of FD is not known. MAS represents in approximately 
5% of all FD patients, usually associating with polyostotic but 
occasionally also with monostotic FD.
Although each separate manifestation of MAS is well known, 
there are only few studies reporting the typical clinical presenta-
tion and outcome in pediatric patients with polyostotic FD. In this 
study, we describe clinical features of polyostotic FD and MAS in 
a Nordic cohort including all pediatric patients with polyostotic 
FD in two tertiary referral hospitals in Finland and Sweden.
sUBJecTs anD MeThODs
subjects
Our retrospective cohort study included all pediatric and adoles-
cent patients with polyostotic FD and MAS who were followed 
in two tertiary hospitals, both largest hospitals in the respective 
countries: Children’s Hospital, Helsinki University Hospital, 
Helsinki, Finland (n  =  7) and Astrid Lindgren’s Children 
Hospital, Karolinska University Hospital, Stockholm, Sweden 
(n =  9). Patients had been referred to hospital care based on 
clinical reasons. For this study, we reviewed retrospectively the 
clinical data for all patients who were diagnosed and followed 
with polyostotic FD between 1996 and 2017 in Stockholm and 
between 2004 and 2017 in Helsinki. Due to centralized care, the 
cohort includes the majority of pediatric patients with polyos-
totic FD in these two countries. In Finland, Children’s hospital 
has been a referral center for the whole country for pediatric 
patients with rare bone diseases since 2004. In Sweden, most 
pediatric patients with polyostotic FD and MAS are diagnosed 
or followed at Karolinska University Hospital. We therefore esti-
mate that our cohort includes close to 100% of the Finnish and 
over half of the Swedish pediatric patients with polyostotic FD 
and MAS during the study period. Diagnosis of polyostotic FD 
was based on clinical, radiological, and histological findings; no 
genetic analyses were performed upon diagnosis. The diagnosis 
of MAS was defined as polyostotic FD together with any extra-
skeletal manifestation (café-au-lait spots and/or any endocrine 
manifestation).
Methods
The clinical data were obtained from the hospital records. For 
growth evaluations, recently published Finnish growth curves 
(12) were used for both Finnish and Swedish patients because 
the growth patterns do not significantly differ between these two 
Nordic populations. A representative growth curve was available 
for 13/16 patients. This retrospective registry study was approved 
by institutional review boards of Helsinki University Hospital, 
Helsinki, and Karolinska University Hospital, Stockholm, and it 
was carried out in accordance with the Declaration of Helsinki. 
Individual patient data in the tables are only shown categorized 
(age; areas of affected bones; etc.) so that patients cannot be 
identified.
The descriptive statistics were generated using IBM SPSS 
Statistics software for Windows, Version 23.0 (IBM Corp., Armonk, 
NY, USA).
resUlTs
cohort characteristics
Our cohort included eight pediatric patients with MAS and eight 
patients with polyostotic FD only. Based on the background 
population of 15 million, and approximately 20% (3 million) of 
them in pediatric age group, this corresponds an estimated preva-
lence of 1 per 375,000 for MAS. The study cohort included eight 
(50%) females and eight males. Median age at last follow-up visit 
was 13.5 years (range 5.3–18.9). Median follow-up time from the 
diagnosis was 8.6 years (range 0–15.9). The clinical characteristics 
are presented in Table 1.
Diagnostic Features and general 
characteristics
The median age at diagnosis of polyostotic FD was 5.0  years 
(range 0.74–11 years), whereas the median age at first symptom 
of the disease was 3.5  years (range 0–8.5). Among the MAS 
patients, the median age at first symptom was 2.7 (0.25–7.3) 
and that at diagnosis 3.6 (range 1.8–8.1) years. In the patients 
TaBle 1 | Clinical characteristics of the Nordic cohort of pediatric patients with polyostotic fibrous dysplasia (n = 16).
Patient age category 
(years) at first 
symptom
Time from first 
symptom (years) 
to dg
Presenting  
manifestation
Mas café-au-lait endocrine  
involvement
hypophosphatemiaa
1 6–9 0.0 Pathological fracture (femur) − − − +
2 6–9 0.0 Prominence of skull − − − +
3 3–6 0.0 Pain; abnormal gait − − − +
4 0–3 1.0 PP + + + PP +
5 6–9 0.2 Impaired vision − − − +
6 0–3 0.4 Several café-au-lait skin patches + + + PP +
7 6–9 0.6 PP + + + PP +
8 0–3 0.4 Pathological fracture (femur) + + Abnormal testicle 
consistence
+
9 6–9 2.8 Abnormal position of left eye (distally) − − − −
10 0–3 0.4 Pain; abnormal gait + + Abnormal testicle 
consistence
+
11 0–3 7.8 PP + + + PP +
12 0–3 0.4 Head asymmetry − − − −
13 0–3 10.8 Face asymmetry − − − −
14 3–6 0.0 Pathological fracture (tibia) + + + PP −
15 3–6 0.1 Abnormal gait after trauma + + Abnormal testicle 
consistence
+
16 6–9 3.0 Headache − − − −
Age categories: 0–3 = from newborn to 2.9 years, 3–6 = from 3.0 to 5.9 years, and 6–9 = from 6.0 to 9.0 years.
MAS, McCune–Albright syndrome; PP, precocious puberty.
aEver presented with hypophosphatemia compared with reference range for age.
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with polyostotic FD only, median age at first symptom and at 
diagnosis were 6.0 (0.0–8.5) and 7.3 (0.7–11) years, respectively.
The first manifestation of the disease in polyostotic FD with-
out MAS (n = 8) was facial or skull asymmetry (n = 4), abnormal 
gait (n =  1), pathological fracture (n =  1), headache (n =  1), 
and impaired vision (n = 1). In patients with MAS (n = 8), the 
first manifestation was PP in three girls, café-au-lait lesions in 
two girls, abnormal gait in two and fracture in one. In most 
children, the diagnosis of polyostotic FD or MAS was set within 
a few months of symptom onset. In one female subject, MAS 
first presented with vaginal bleeding in infancy, but diagnosis 
of MAS was made only several years later, at 8.1  years of age, 
when she manifested with skeletal symptoms. In addition, one 
girl presented with facial asymmetry already at birth but was 
diagnosed with craniofacial FD only at 10.8 years, and another 
girl with multiple café-au-lait spots in infancy was diagnosed 
with MAS at the age of 2 years, when she developed precocious 
gonadotropin-independent puberty.
skeletal lesions, Fractures, and 
Orthopedic surgery
To evaluate the affected skeletal areas, bone scintigraphy was 
performed in altogether nine subjects, in seven of seven Finnish 
and in two of nine Swedish patients. In most of the Swedish 
patients, plain radiographs were used to evaluate the distribution 
of FD lesions. In addition, craniofacial engagement was evaluated 
with magnetic resonance imaging (MRI) or CT in 11 patients. 
The extent of skeletal involvement is described in Table  2. 
Craniofacial bone involvement was found in 12/16 patients, and 
almost half of these (5/12; 42%) had compression of optic nerve. 
Of the five affected, one subject had lost vision unilaterally due to 
optic nerve damage at 6 years of age, and another two presented 
with unilateral exophtalmos at the ages of 4 and 9 years. The most 
commonly affected craniofacial bones were the maxillar (n = 9) 
and orbital (n = 8) bones.
Most commonly affected bones in extra-cranial skeleton 
were the femur (n = 9) and tibia (n = 6). Three of the 16 subjects 
(19%) presented with scoliosis. It was associated with extensive 
FD lesions at the lumbar spine, pelvis, and hip in one patient, 
and by FD lesions at ileum in another patient. The third affected 
patient had pronounced neuromuscular scoliosis. Altogether 11 
(69%) patients (7/8 of those with MAS) had sustained at least 
one fracture by the end of follow-up; most of them had had 
several fractures in the same affected bone. All but one of those 
without fracture history had FD lesions only in multiple bones at 
cranial or facial area. In turn, only one of the five patients with solely 
craniofacial involvement had sustained a (traumatic) fracture (in 
nasal bone). Of those with a fracture history, 8/11 had hypophos-
phatemia as compared with 2/5 of those without a fracture. In 
six patients (55% of those with a fracture), the fracture(s) were 
surgically treated. In total, nine patients (56% of all) had needed at 
least one orthopedic surgery because of the FD lesions (Table 2).
Recurrent headaches were reported by 5 of the 12 patients with 
craniofacial FD lesions. Recurrent pain was reported by altogether 
seven (44%) patients. The most severe skeletal manifestations of 
polyostotic FD were recurrent fractures in the weight-bearing 
long bones, mostly in the proximal femur.
endocrine Features and growth
Altogether 8 (5/8 girls, 3/8 boys) of the 16 patients with polyos-
totic FD (50%) were defined as having MAS (Table 1). Among 
those with MAS, five girls presented with PP and three boys 
with abnormal testicles, characterized as having firm, irregular 
TaBle 2 | Affected bones, fractures, and surgical operations in pediatric patients with polyostotic fibrous dysplasia (n = 16).
Patient 
number
age 
category 
(years)a
height 
sDsa
affected bones craniofacial 
involvement
Fractures Orthopedic (or other)  
surgery
Orthopedic 
disabilities/problems
chronic pain/
head aches
1 10–15 −0.5 Ribs, ilium, and femur − + Fixation of femoral fracture −
2 15–20 +0.2 Orbital and parietal bones + − − −
3 15–20 −0.5 Pelvis and femur − + Epiphysiodesis and spondylodesis Disabling deformity of 
pelvis and hip
4 10–15 −0.2 Orbital, maxillar, frontal, sphenoidal, temporal, mandibular bones, 
humerus, fibula, tibia, and femur
+ Stenosis of 
nervus opticus
+ Fixation of femoral fracture; 
osteotomy
− + Headaches
5 15–20 +0.4 Sphenoidal, frontal and orbital bones unilaterally + Stenosis of 
nervus opticus
− (Decompression of optic nerve) − + Headaches
6 15–20 −1.7 Skull base, parietal, occipital, orbital, temporal, humerus, fibula,  
tibia, and femur; all unilaterally
+ + Fixation of femoral fracture times 3; 
correction of coxa valgus deformity
− + Headaches
7 15–20 +0.5 Occipital, parietal, maxillar, mandibular bones, humerus, radius,  
femur, and tibia
+ + − −
8 5–10 N/Ab Ceiling of orbita, maxillar, mandibular, frontal, ethmoidal, sphenoidal, 
temporal, occipital, and parietal bones, femur, tibia, and fibula
+ + Fixation of femoral neck bilaterally; 
osteotomy
Severe scoliosis
9 15–20 +0.1 Sphenoidal, maxillar, and ceiling of orbita unilaterally; frontal bone, 
foramina optica bilaterally
+ Stenosis of 
nervus opticus
− − − + Headaches
10 15–20 −1.3 Skull base (mostly unilaterally): frontal, sphenoidal, orbital, maxillar,  
and temporal bones; pelvis, femur bilaterally
+ Stenosis of 
nervus opticus
+ Femoral osteosynthesis bilaterally − Chronic pain
11 10–15 +1.6 Femur and fibula bilaterally; tibia, skull base (widely), mandibular, 
zygomatic, maxillar bones, humerus, and orbital bones
+ Stenosis of 
nervus opticus
+ − Varus malalignment 
of hip
Chronic pain
12 10–15 −0.3 Frontal, parietal, and ethmoidal bones, concha superior, sinus 
maxillaris unilaterally, and sinus ethmoidalis bilaterally
+ + (Skull operation) −
13 10–15 +0.5 Maxillar and sphenoidal bones, fossa cranii media + − − −
14 10–15 −1.3 Tibia (widely), fibula unilaterally − + − −
15 5–10 +1.2 Pelvis, femur, tibia, talus, humerus, and radius − + + Fixation of femur fracture with 
osteosynthesis; osteotomy
−
16 10–15 −0.1 Maxillar bone bilaterally + − − − + Headaches
SDS, standard deviation score.
aAge and height SDS at last follow-up visit.
bHeight measure not possible; arm span used as a proxy for height.
4
U
triainen et al.
P
olyostotic FD
/M
A
S
—
c
hildhood M
anifestations
Frontiers in Endocrinology | w
w
w
.frontiersin.org
M
arch 2018 | Volum
e 9 | A
rticle 96
FigUre 1 | Growth curves of the boys with polyostotic fibrous dysplasia with MAS (a) and without MAS (B–F).
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consistence, and abnormal structure in testicles either unilater-
ally or bilaterally. In two of these, testicular ultrasound showed 
microcalcification. These testicular changes were not associated 
with abnormal testosterone production and timing of pubertal 
development was normal in these patients.
Thyroid function was normal in all subjects; thyroid imag-
ing was not routinely performed in our patients. None of the 
subjects presented with overt GH excess; circulating IGF-1 levels 
were within the normal range for age in those with measure-
ments. Growth in height and head circumference were closely 
monitored, and none had a growth curve suggestive of GH excess 
(Figures 1 and 2).
All subjects had been born full term and with appropriate size 
for gestational age with median birth length (n = 15) of 51 cm 
(range 48–54) and weight 3.5  kg (3.2–4.6). The median height 
Z-score at FD diagnosis (n = 15) was +0.50 (range −1.70 to +3.50) 
and at the end of follow-up, +0.05 (range −1.8 to +1.6); none of 
the subjects presented with short stature (height Z-score < −2.0). 
Among the five girls with PP, height Z-score was on average +1.5 
at FD diagnosis (range −1.0 to +3.5) and −0.20 at the end of 
study follow-up (range −1.8 to +1.6) (Table 3). Prepubertal and 
pubertal growth were within the normal reference range in all 
males (Figure 1), and in female patients without MAS (Figure 2). 
Two male MAS patients in whom we did not have growth curves 
available also had normal growth in height: one at −1.5 SD and 
the other at +2.0 SD curve. One girl with MAS and PP presented 
with slightly compromised final height, but still within the nor-
mal range, while other girls had normal pubertal growth pattern 
(Figure 2).
Pubertal timing was within the normal range in all males and 
all females without MAS. The three girls with polyostotic FD but 
no MAS had the menarche at 12.5, 12, and 13 years.
Two of the five PP girls were treated with a combination of 
estrogen blocker (clomifen) and GnRH agonist (leuprorelin). 
The remaining three MAS girls with PP were followed without 
hormonal treatment for PP. In one of these, fluctuation of circu-
lating estrogen level could be demonstrated biochemically. In the 
two girls treated with clomifen and leuprorelin, vaginal bleeding 
could be prevented, and further bone age advancement could 
be blocked. Both of them also reached normal post-pubertal 
height (Figure 2). PP girls without hormonal treatment also had 
heights within the normal range at pubertal or post-pubertal age 
(Figure 2). The treatment and growth characteristics of the PP 
girls are shown in Table 3.
Brain MRI or CT was performed as part of diagnostic work-up 
or in the follow-up of 11 of 12 subjects with craniofacial lesions. 
None had pituitary adenomas or other neoplasms on imaging.
Other clinical and Biochemical Features
All eight subjects with MAS presented with café-au-lait spots. 
Altogether 11 of our 16 patients had presented with mild 
hypophosphatemia (plasma phosphate below the reference range 
for age) and hyperphosphaturia. Serum FGF-23 was measured in 
four of seven Finnish patients, and it exceeded the upper refer-
ence range for age in all but one of them. None of the patients had 
received treatment for mild hypophosphatemia as none presented 
with muscle weakness or other symptoms of hypophosphatemia, 
or radiographic features of hypophosphatemic rickets.
One female patient had congenital hepatopathy with neonatal, 
transient hepatomegaly, and elevated liver enzymes, and she later 
developed inflammatory bowel disease at adolescence. No other 
subjects had a history of any hepatic, biliary, or pancreatic disor-
ders or biochemical abnormalities in liver function. Abdominal 
ultrasound or MRI was performed in additional three of the 
seven Finnish patients for other reasons, for example, due to 
unspecific abdominal pain, and they all showed normal findi-
ngs. Abdominal ultrasound or other imaging studies were not 
routinely performed in our cohort patients.
Three patients required psychological assessment and support. 
All these patients reported also recurrent headache or other pain.
DiscUssiOn
This study reports the clinical spectrum of polyostotic FD in a 
non-selected pediatric cohort. Our cohort included all pediatric 
patients with polyostotic FD in two Nordic tertiary referral cent-
ers between 1996 and 2017.
As expected, the spectrum of skeletal manifestations was 
wide, from few lesions with mild or no symptoms to wide-spread 
disabling disease with pain and joint involvement.
TaBle 3 | Height and bone age at commencement of peripheral PP, and at the end of follow-up (at 12–15 years of age), in five girls with McCune–Albright syndrome 
and PP.
Patient 
number
age category 
(years) at PP
Ba advancement 
(years)a at PP
height sDs at PP Treatment of PP Ba advancementa  
at follow-up (years)
current height 
sDs
Parental  
height sDss
4 1–4 +0 +0.8 (+1.6 at dg) Clomifene (4 years–>);  
leuprorelin (7 years–>)
−1.4 −0.5 Fa −0.3
Mo +0.6
6 1–4 +1.2 +2.0 Clomifene (3 years–>);  
leuprorelin (11 years–>)
−2.2 −1.8 Fa +1.0
Mo +0.0
7 5–8 +0 +1.4 No treatment +0.2 +0.5 Fa −0.3
Mo +0.8
11 <1 N/A N/A (+3.5 at dg) No treatment +2.2 +1.6 Fa −0.3
Mo −0.1
14 1–4b N/A −0.9 No treatment N/A −1.1 Fa −0.3
Mo +0.1
aBoneExpert according to G-P; BA advancement = BA − CA.
bTanner B2 by 4 years of age, but spontaneous recovery to B1 before progressive pubertal development.
PP, precocious puberty; BA, bone age; CA, calendar age; Fa, father; Mo, mother; N/A, not available.
FigUre 2 | Prepubertal and pubertal growth in height in female patients with polyostotic fibrous dysplasia (FD). Growth curves of the five girls with FD and 
McCune–Albright syndrome (MAS) manifesting with peripherally driven precocious puberty (PP) (a–e). One of the MAS girls (a) had enhanced early growth together 
with bone age advancement, and she ended up with slightly compromized adult height. Other MAS patients with PP had normal growth and height at the end of 
follow-up. (F,g) Growth curves of the two girls with polyostotic FD but no MAS.
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Polyostotic FD was part of MAS in half (8/16) of the patients. 
All of them presented with café-au-lait spots. In addition, appro-
ximately two-thirds of girls had PP, and one-third of boys had 
testicular involvement, with no other endocrinopathies. None 
of the patients manifested with hyperthyroidism or overt GH 
excess. Mild hypophosphatemia as a result of FGF-23-mediated 
hyperphosphaturia was evident in two-thirds of the patients. In 
the largest reported FD cohort (NIH cohort) by Collins and cow-
orkers, PP was found in 50% of the female patients and gonadal 
abnormalities in 70% of the male patients. In the same cohort, 
café-au-lait spots were found in 66%, renal phosphate wasting 
in 43%, thyroid abnormalities in 66% (28% with hyperthyroid-
ism), and GH excess in 21% of the patients (8). The prevalence 
of skin manifestation and PP in our cohort is well in agreement 
with that study, while the lower prevalence of testicle and thyroid 
abnormalities might be explained by the lack of routine ultra-
sound of testicles and thyroid gland in our cohort. However, there 
was a clear difference in the prevalence of hyperthyroidism and 
GH excess, which were found in one-fourth of the NIH cohort 
patients but in none in our cohort. The lack of a wider spectrum 
of endocrinopathies in our cohort is probably partly explained 
by small sample size, and partly by the non-selected population 
including also patients with milder form of the disease. Our 
cohort is likely to be a more representative sample of pediatric 
patients with polyostotic FD in tertiary hospitals while the NIH 
cohort may be biased toward more complicated patients.
Our finding of macro-orchism and testicular microcalcifica-
tion without abnormal hormone secretion has been reported in 
7Utriainen et al. Polyostotic FD/MAS—childhood Manifestations
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a few previous studies (13, 14). Serum IGF-I and growth pattern 
in height and head circumference were closely followed in our 
pediatric patients, but none of them had signs of GH overexpres-
sion. Lack of GH excess in our sample may be partly explained 
by the young age of our patients. In a previous study, the median 
age at the diagnosis/manifestation of acromegaly was 24 years of 
age, and GH excess was associated with accelerated growth in 
85% of pediatric patients (9). Moreover, acromegaly was almost 
always associated with skull base FD, and half of the patients had 
adenoma in CT or MRI. By contrast, none of our patients with 
craniofacial FD had pituitary abnormalities in cranial imaging 
studies. However, the possibility of GH excess warrants close 
monitoring of the patients with cranial base involvement (9).
The presenting complaint in our patients with polyostotic FD 
was variable. Café-au-lait skin spots had assumingly been the first 
manifestation in most MAS patients, but they often remained 
unnoticed by both parents and doctors. In girls with MAS, PP was 
usually the first overt manifestation of the disease. In one female 
patient, the diagnosis of FD was reached several years after PP, 
since the girl had no clinical signs of skeletal manifestation at the 
time of PP, and skeletal imaging/scintigram was not performed 
upon onset of PP. On the other end of disease spectrum, the 
presenting complaints in polyostotic FD patients without MAS 
included fractures, abnormal gait, impaired vision, and headache. 
Due to the wide spectrum of possible first symptoms, polyostotic 
FD with or without MAS still remains a diagnostic challenge. It 
is notable that café-au-lait spots could have revealed all the MAS 
patients already at young age in this cohort. Thus, the diagnosis 
of MAS should be considered in patients with wide-spread café-
au-lait changes, especially if typical for MAS (“coast of Maine”), 
even without any other clinical signs of the disease as these may 
develop much later. MAS should also be kept in mind as an alter-
native diagnosis in patients evaluated for neurofibromatosis. As 
for those with polyostotic FD without MAS, craniofacial asym-
metry and plain radiographs in case of fractures could usually 
lead to the diagnosis.
Majority of the patients in our cohort had sustained a fracture 
(11/16). This is in agreement with a previous study on fracture 
risk in FD (15). As assumed, several refractures often occurred in 
the bones with fibrotic lesions. Especially femoral fractures often 
needed one or multiple surgical fixations. Hyperphosphaturia 
was slightly more common in those with a fracture history than 
in those without fractures, but no definitive conclusions can be 
drawn because of the small sample size, especially since some 
patients had only craniofacial lesion with low fracture risk. One 
of the five patients with optic nerve compression had lost vision 
unilaterally, which underlines the need for MRI follow-up in 
craniofacial FD. Other symptoms affecting the quality of life 
were recurrent headaches in almost one-third of our patients. 
The relatively high rate of mental problems related to chronic 
pain in our cohort is in line with a recent questionnaire study 
in a large Dutch FD cohort showing impaired quality of life 
compared with general population (16). Pain is a common 
feature in FD and may be underestimated especially in pediatric 
patients (17).
To the best of our knowledge, this is the first study to report 
growth characteristics in pediatric patients with polyostotic 
FD or MAS. In our cohort, all subjects were born with weight 
and height appropriate for gestational age. On average, height 
Z-scores were within normal reference range at diagnosis and at 
the last follow-up visit. Prepubertal and pubertal growth pattern 
was normal in all subjects without MAS, suggesting that their 
gonads are not affected by the activating GNAS mutation. On 
the other hand, over half of our MAS patients with peripherally 
driven PP were followed without treatment, and they also had 
normal growth and seemed to reach normal adult height. In the 
two PP girls with more severe PP, the outcome of treatment with 
estrogen blocker and GnRH agonist was satisfactory, although 
one of the girls ended up with slightly shorter final height than 
expected by parental height Z-scores.
The best treatment modality for peripheral, gonadotropin-
independent PP in MAS patients has remained unclear (6, 18). 
A recent and largest study on PP treatment in MAS reported safe 
and beneficial effect of aromatase inhibitor letrozole on skeletal 
maturation, growth velocity, and predicted adult height (19). In 
our retrospective cohort, two girls with PP had been treated with 
a combination of antiestrogen and GnRH agonist; they were both 
treated before the era of aromatase inhibitors in the PP treatment. 
Most of the PP girls in our series did not need any hormonal 
treatment for PP due to slow progress of puberty. This indicates 
that the early peripherally driven puberty is not always rapidly 
progressive in MAS, and watchful wait may be the best option 
for them. On the other hand, if untreated estrogen excess leads 
to early maturation of the central pubertal axis, treatment may 
be challenging with the combination of antiestrogen and GnRH 
agonist.
In general, the prevalence of MAS is estimated to be 1 per 
100,000–1,000,000 (6). With the background population of 
our pediatric/young adult cohort being approximately three 
million people, our cohort of eight MAS patients gives an esti-
mated prevalence of 1:375,000, which is within the previously 
reported range. This indicates that our cohort represents the 
vast majority of pediatric MAS patients in these two countries. 
As for polyostotic FD, our cohort includes all severely affected 
patients, but some milder cases may be missed, if they have 
been treated and followed in smaller institutes. Although our 
cohort included the majority of MAS and polyostotic patients 
in our population, the sample size is small, which is the main 
weakness of the study.
In conclusion, MAS still remains a diagnostic challenge, 
and delayed diagnosis may have significant consequences. 
The prevalence of thyroid and GH excess seems to be low in 
pediatric MAS patients but follow-up until adulthood with 
careful endocrine assessments is warranted. Skeletal outcome 
of polyostotic FD can be severe and disabling, and craniofacial 
lesions can even lead to permanent vision loss. Therefore, 
craniofacial FD should be closely monitored with skull MRI 
in childhood to enable early detection of optic nerve compres-
sion. Chronic pain is a significant complication and needs to 
be assessed during follow-up visits in children with polyostotic 
FD. Pediatric patients with polyostotic FD and particularly with 
MAS should be followed in tertiary hospitals with experience 
on these rare patients with strikingly broad spectrum of disease 
manifestations.
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